aTyr Pharma, Inc.
Narrative signal
aTyr Pharma, Inc.’s revenue growth stands at -33.4% for Dec 2024. Year-over-year, the metric shifted by +63.2 pts, translating into a +65.4% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
Valuation Signals
Track how the market prices earnings, book value, and operating cash flow for rapid context on relative multiples.
Price-to-Earnings Ratio
-4.2x
Price-to-Sales Ratio
1,143.9x
Price-to-Book Ratio
3.8x
EV / EBITDA
-4.1x
Dividend Yield
0%
Profitability Pulse
Follow margin structure and return ratios that benchmark execution quality and capital efficiency.
Growth Momentum
Gauge the trajectory of revenue, earnings, and free cash flow expansion to understand durability.
Cash & Balance Sheet
Monitor liquidity, leverage, and free cash flow capacity that underpin resilience across cycles.
AlphaPilot quick take
• aTyr Pharma, Inc. trades at $0.8239 with a market footprint around $80.7M.
• Operating within Healthcare — Biotechnology offers instant peer context.
• Dashboard highlight: revenue growth at -33.4%, refreshed from the live fundamentals feed.
• Pivot into AlphaPilot deep dives to benchmark valuation, execution, and resilience.
Company profile
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
aTyr Pharma, Inc. (ATYR) stock FAQs
Quick answers sourced from live Financial Modeling Prep fundamentals and AlphaPilot portfolio guidance.
What is aTyr Pharma, Inc. (ATYR) stock price today?
aTyr Pharma, Inc. (ATYR) trades near $0.8239 as of Dec 5, 2025, 9:00 PM. Quotes refresh throughout the trading day in USD via Financial Modeling Prep, which powers the AlphaPilot dashboard.
What is aTyr Pharma, Inc.'s market capitalization?
aTyr Pharma, Inc.'s equity is valued around $80.7M, based on the latest share price multiplied by shares outstanding reported to Financial Modeling Prep.
What is the 52-week range for aTyr Pharma, Inc.?
aTyr Pharma, Inc.'s 52-week range runs from $0.64 — $7.29. Comparing the current price to this band helps visualize positioning versus the past year's highs and lows.
How active is trading in aTyr Pharma, Inc. stock?
aTyr Pharma, Inc. most recently moved about 1.4M shares. Elevated volume often signals strong investor interest or fresh catalysts.
Does aTyr Pharma, Inc. pay a dividend?
aTyr Pharma, Inc. currently yields roughly 0%. Dividend yield divides the last 12 months of payouts by the latest share price, providing a quick income snapshot.
What is aTyr Pharma, Inc.'s intraday trading range?
aTyr Pharma, Inc. has traded between $0.81 — $0.8499 so far today. Monitoring the intraday span highlights short-term volatility relative to the longer 52-week range.
Where does the aTyr Pharma, Inc. stock data come from?
AlphaPilot sources quotes, fundamentals, and intraday chart data for aTyr Pharma, Inc. from the Financial Modeling Prep institutional API. The summary page blends live pricing with fundamentals that refresh after every earnings release or regulatory filing.